each subject, we calculated voxelwise statistical parametric maps (SPMs) of D2/D3 receptor availability and amphetamine-induced DA release (percent change in [ 18 F]-fallypride binding from placebo; Fig. S1 ), and correlated these SPMs with participants' BIS-11 total scores (6) .
Trait impulsivity was inversely correlated with D2/D3 autoreceptor availability in the substantia nigra/ventral tegmental area (SN/VTA; Fig. 1A) , and positively correlated with the magnitude of amphetamine-induced DA release in the striatum (Fig. 1A) . Consistent with an inhibitory influence of midbrain autoreceptors on DA release in terminal fields (7), SN/VTA D2/D3 binding potential was inversely correlated with bilateral striatal DA release following amphetamine (r = −.42/−.35, left/right striatum, both p's < 0.05). Using path modeling (mediation analysis), we tested our mechanistic hypothesis that lower SN/VTA D2/D3 availability leads to impulsive traits by enhancing stimulated DA release in the striatum. This analysis confirmed that the ability of SN/VTA D2/D3 binding to predict impulsive temperament is at least in part mediated through the impact of SN/VTA D2/D3 availability on amphetamine-induced DA release in the striatum (Fig. 1B) .
To examine the relevance of enhanced striatal release to risk for psychopathology, we examined the relationship between amphetamine-induced striatal DA release and subjective responses to amphetamine. Increased striatal DA release predicted stronger subjective desire for more drug following amphetamine treatment (drug "Wanting" from the Drug Effects Questionnaire; left/right striatum: r = .48/.47, both p's < 0.01). Given that heightened subjective "wanting" responses to initial psychostimulant exposure is a significant risk factor for future drug dependence (8) , and that BIS-11 scores have been found to predict drug craving in substance dependent individuals (9), the present data suggest a neurobiological link between human impulsiveness and drug abuse vulnerability.
These results show that individual differences in midbrain D2/D3 availability are associated with the expression of impulsivity in humans, an effect that appears to be mediated, in part, through diminished inhibitory autoreceptor control over stimulated striatal DA release. Our findings suggest that dysregulation within ascending dopaminergic projection pathways subserving reward and motivation may produce deficits in impulse control, a critical feature of the psychopathological architecture underpinning substance abuse. Further, they provide a specific, plausible mechanism that links individual variability in DA network functioning to differences in human impulsivity. (B) Path analysis demonstrating that the influence of midbrain D2/D3 availability on trait impulsivity is mediated through an impact on striatal amphetamine-induced DA release. Path "A" shows path coefficients for the effect of midbrain D2/D3 binding (cluster highlighted with red circle) on striatal DA release (left/right striatum). Path "B" shows the path coefficient for the effect of striatal DA release on trait impulsivity (left/right striatum). Paths "C" and "C'" show coefficients for the total (dashed line) and direct (solid line) effects of midbrain D2/D3 binding on trait impulsivity. All coefficients standardized. Sobel test for mediation: Z = −1.94, p = 0.05, with left and right striatum modeled simultaneously.
